Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study on Tolerance and Safety of Vemurafenib Film-coated Tablets, Cetuximab Solution for Infusion and Camrelizumab Protocol(VCC) in the After Line Therapy of BRAF V600E Mutation/MSS Metastatic Colorectal Cancer

NCT05019534 is registered in ClinicalTrials.gov with West China Hospital as lead sponsor.

NCT NCT05019534
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05019534 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study on Tolerance and Safety of Vemurafenib Film-coated Tablets, Cetuximab Solution for Infusion and Camrelizumab Protocol(VCC) in the After Line Therapy of BRAF V600E Mutation/MSS Metastatic Colorectal Cancer
Lead sponsor
West China Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
August 15, 2021
Completion date
December 1, 2022
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

braf v600e-mutated /mss metastatic colorectal cancer, vemurafenib (brafi) plus cetuximab (egfri) combined with pd-1 monoclonal antibody